[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331768-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331768-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-role-of-pulmonary-metastasectomy-for-non-primary-lung-cancer-umbrella-review-of-meta-analyses","The Role of Pulmonary Metastasectomy for Non-Primary Lung Cancer - Umbrella Review of Meta-Analyses","","Umbrella review of meta-analyses evaluates pulmonary metastasectomy (PM) in non-primary lung cancers, addressing gaps caused by heterogeneous primary tumor biology. The study systematically searched meta-analyses on PM up to January 3, 2024, including seven cancer types (renal cell, breast, adrenocortical, head and neck, melanoma, germ cell tumors, and sarcoma). Outcomes focused on overall survival and post-PM recurrence using random-effects models, incorporating 16 systematic-review articles and 101 individual studies (10,277 patients).",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-role-of-pulmonary-metastasectomy-for-non-primary-lung-cancer-umbrella-review-of-meta-analyses/331768/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-role-of-pulmonary-metastasectomy-for-non-primary-lung-cancer-umbrella-review-of-meta-analyses/331768.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about pulmonary metastasectomy (PM)?","Question",{"text":63,"@type":64},"It examines how effective PM is for non-primary lung cancers, focusing on clinical outcomes such as overall survival and recurrence.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the eligible studies for the umbrella review selected?",{"text":68,"@type":64},"Meta-analyses on PM for non-primary lung cancers were searched up to January 3, 2024, and included seven primary cancer categories; overall survival and recurrence were synthesized using random-effects models.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key outcomes after PM in this analysis?",{"text":72,"@type":64},"Complete resection was reported in 87.2%, the pooled 5-year overall survival rate was 41.2%, and recurrence occurred in 57.6% during follow-up, with intrathoracic-only recurrence in 48% of recurrent cases.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331768,1790202544,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Journal of  \nSurgical Oncology  \nRESEARCH ARTICLE   \nThe Role of Pulmonary Metastasectomy for Non‐Primary Lung Cancer: Umbrella Review of Meta‐Analyses  \nWongi Woo1  | Brandon Park2 | Awranoos Ahadi3 | Liam il‐young Chung3 | Chan Mi Jung3 | Ankit Bharat3 | Young Kwang Chae3  \n1Department of Internal Medicine, Dignity Health St. Joseph Medical Center Stockton, Stockton, California, USA | 2University of Missouri‐Kansas City School  \nof Medicine, Kansas City, Missouri, USA | 3Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA Correspondence: Young Kwang Chae ([ychae@nm.org](ychae@nm.org))  \nReceived: 8 November 2024 | Accepted: 16 November 2024  \nFunding: The authors received no specific funding for this work.  \nKeywords: lung metastasis | metastasectomy | nonprimary lung cancer | pulmonary metastasis | secondary lung cancer  \nABSTRACT  \nBackground and Objectives: Due to heterogeneous characteristics of primary cancers, the efficacy of pulmonary metastasectomy (PM) in nonprimary lung cancers has not been investigated. This study aims to investigate the clinical outcomes of PM for non‐primary lung cancer.  \nMethods: A systematic search for meta‐analyses on PM for nonprimary lung cancers was conducted, encompassing publications up to January 3, 2024 . This included seven primary cancers: renal cell, breast, adrenocortical, head and neck cancers, melanoma, germ cell tumors, and sarcoma. Overall survival and recurrence rates post‐PM were assessed using random‐effect models.  \nResults: This study included 16 systematic‐review articles and 101 individual studies, involving 10 277 patients who underwent PM for nonprimary lung cancer. About half of the patients (47.1%) presented with multiple metastasis, and complete resection achieved in 87.2% [95% CI: 83.0–90.8] . The pooled 5‐year overall survival rate post‐PM was 41.2% [95%CI: 37.1%–45.4%]. Patients with germ cell tumors demonstrated higher survival rate (p \u003C 0.05), while melanoma exhibited the worst outcome (p \u003C 0.05) . During follow‐up, 57.6%[95% CI: 46.4–68.1] had recurrence; 48% of them had intrathoracic‐only recurrence. Conclusion: This study underscores the survival benefits associated with PM. Overall survival rates following PM did not differ based on primary cancer types. These findings highlight the importance of recognizing and incorporating PM into clinical practice when appropriate.  \n1 | Introduction  \nLung is one of the organs with frequent cancer metastasis. Most patients with lung metastases are primarily treated with systematic treatments [1, 2] . These treatments are designed to control both the primary and distant metastatic lesions. Surgery alone is rarely performed in these metastatic lesions and usually combined with neoadjuvant or adjuvant treatments. However, in cases where the primary cancer is well‐controlled,  \npulmonary metastasectomy (PM) may be pursued to achieve oncologic cure and/or survival benefits.  \nPM was first performed in 1939 for renal cell cancer metastasis [3], and pneumonectomy for extensive lung metastasis was first done in 1958 [4] . After several reports were published, its clinical benefits have been widely accepted, with PM now constituting 10.2% of all general thoracic surgeries in Japan [5] . The number of PM procedures in the United States has also  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.  \n© 2024 The Author(s) . Journal of Surgical Oncology published by Wiley Periodicals LLC.  \nJournal of Surgical Oncology, 2025; 131:1035–1043 1035 of 1235  \n[https://doi.org/10.1002/jso.28033](https://doi.org/10.1002/jso.28033)  \nincreased over time, with improvements in surgical techniques and reduced perioperative morbidity/mortality risks [6] .  \nIn terms of primary cancer types, ","cbCaiiNkxs91zFgC","https://ap.wps.com/l/cbCaiiNkxs91zFgC","pdf",835468,"English","# Abstract\n## Background and Objectives\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Methods\n## Search Strategy and Eligibility Criteria","[{\"question\":\"What question does the study address about pulmonary metastasectomy (PM)?\",\"answer\":\"It examines how effective PM is for non-primary lung cancers, focusing on clinical outcomes such as overall survival and recurrence.\"},{\"question\":\"How were the eligible studies for the umbrella review selected?\",\"answer\":\"Meta-analyses on PM for non-primary lung cancers were searched up to January 3, 2024, and included seven primary cancer categories; overall survival and recurrence were synthesized using random-effects models.\"},{\"question\":\"What were the key outcomes after PM in this analysis?\",\"answer\":\"Complete resection was reported in 87.2%, the pooled 5-year overall survival rate was 41.2%, and recurrence occurred in 57.6% during follow-up, with intrathoracic-only recurrence in 48% of recurrent cases.\"}]","The Role of Pulmonary Metastasectomy for Non-Primary Lung Cancer - Umbrella Review of Meta-Analyses | PDF",1789995028,23]